Take your project to the next level with high-quality recombinant antibody production services at evitria.
From sequence to antibody in 4 weeks
We know how tight timelines in biotechnological projects can be. With resources and know-how at hand, our efficient workflow allows us to provide you with recombinant antibodies within only 4 weeks. Starting with a pilot study, large-scale expression commences after 2 weeks, followed by purification, extensive analytics, and – finally – shipment of the deliverables to our customers worldwide.
Week 1
Week 2
Week 3
Week 4
Pilot Study*
Larger-scale expression
Purification
Final analytics
Shipment
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Business days
Ensure your project starts on the right track!
Regardless of where your research is taking you, Julia Pizzolato, PhD, guides you through the critical decisions in your project.
Connecting directly with an experienced scientific liaison allows you to bridge the gap between initial candidate design and scalable recombinant production.
Bring your specific project questions to a focused session and get clear, actionable insights to move forward with complete confidence.
Custom recombinant antibody production service – take advantage of more than a decade of experience
With over a decade in recombinant antibody production, evitria has become a trusted partner for clients worldwide. Since 2010, we have performed over 140,000 transfections and purified more than 20,000 antibodies for customers from academic laboratories to global biopharmaceutical companies.
Our expertise encompasses a wide range of expression services, including:
Isotype switching
Chimerization
Antibody humanization
Glyco-engineering
Bispecific and trispecific antibodies
Fusion antibodies, including Fc fusion proteins
Whether you need a partner for your complete antibody production or support with specific projects, our team provides tailored, reliable, and reproducible solutions.
Long-lasting, healthy customer relationships are very
important to us. Anonymity is therefore part of our corporate DNA.
“We have been working with evitria for several years and highly appreciate the high consistency of the delivered material.”
Sr. Scientist, Biotherapeutics, Switzerland
“We have been working with evitria since 2022. We appreciate the openness and flexibility of the team, the high speed and quality of the proteins they deliver.”
Radiopharm Theranostics Ltd.
“We are happy paying for the assured quality that evitria brings.”
Sr Scientist, Biotherapeutics, Series B Startup, Boston
Recombinant monoclonal antibody production in CHO cells
Our CHO cell-based expression platform produces recombinant monoclonal antibodies with high purity, exceptional quality, and efficiency. Unlike Escherichia coli and other bacterial expression systems, CHO cells can achieve complex human-like post-translational modifications.
Transient expression of antibody genes in CHO cells also eliminates the need for laboratory animal immunization, resulting in products free from animal contamination and ethical concerns.
This method also enables shorter timelines and higher yields than traditional techniques (e.g. hybridoma technology), delivering fully functional antibodies that meet the rigorous demands of modern research and therapeutic applications.
Studies confirm that with a reliable system, these high-quality, transiently expressed antibodies can meet the necessary standards for clinical evaluation. An early commitment to scalable, reproducible expression methods is key for a successful transition to GMP manufacturing, regulatory approval, and commercial production.
For the removal of residing reagents, amino acids and other byproducts, protein A purification is standard in biotechnology, and we use alternative resins such as Protein G, L, Kappa/Lambda-Select or anti-IgG-CH1 as needed. An additional size exclusion chromatography (SEC) purification step can be added, as well as ion exchange chromatography. Please inquire for more details
Our average timeline is between 4 and 6 weeks for new antibodies. If we have produced the antibody before then reproduction will take 2.5-3.5 weeks.
We have produced both bispecific and trispecific antibodies in various formats. Please contact your local evitria representative to discuss your specific project.
No, but please see our “Partners” page to find best-in-class solutions for required services. We work together with established partners for optimization of mAb and rAb development workflows.
At evitria, we focus on transient antibody production. Thereby, we rely on CHO cells as our expression system of choice, as they come with several advantages in terms of quality and speed.
No, evitria works with partners to ensure maximum value to customers. For sequencing issues in the production of recombinant antibodies, Rapid Novor is evitria’s partner.
Let’s get in touch with our experts now!
Our team of experts looks forward to answering all your concerns regarding our services and solutions.
